​

MoonLake Immunotherapeutics Ownership | Who Owns MoonLake Immunotherapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

MoonLake Immunotherapeutics Ownership Summary

MoonLake Immunotherapeutics is owned by 92.58% institutional investors, 15.33% insiders. Bvf inc/il is the largest institutional shareholder, holding 31.21% of MLTX shares. T. Rowe Price Health Sciences is the top mutual fund, with 1.64% of its assets in MoonLake Immunotherapeutics shares.

MLTX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockMoonLake Immunotherapeutics92.58%15.33%-7.91%
SectorHealthcare Stocks 488.30%11.08%-399.38%
IndustryBiotech Stocks 307.10%11.11%-218.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bvf inc/il19.75M31.21%$932.26M
Cormorant asset management, lp8.49M13.42%$400.92M
Fmr6.34M10.08%$343.39M
Avoro capital advisors4.15M6.56%$195.88M
Price t rowe associates inc /md/3.34M5.32%$181.06M
Paradigm biocapital advisors lp1.77M2.82%$95.97M
Goldman sachs group1.67M2.66%$90.68M
Federated hermes1.28M2.04%$69.31M
Westfield capital management co lp1.26M1.99%$59.44M
Alliancebernstein1.02M1.63%$55.37M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bvf inc/il19.75M33.31%$932.26M
Cormorant asset management, lp8.49M29.86%$400.92M
Saturn v capital management290.78K5.56%$13.73M
Ghost tree capital300.00K4.13%$13.19M
5am venture management282.31K3.65%$15.29M
Avoro capital advisors4.15M3.43%$195.88M
Paradigm biocapital advisors lp1.77M3.34%$95.97M
Bioimpact capital313.57K2.56%$14.80M
Vestal point capital, lp550.00K1.37%$25.96M
Siren508.27K1.24%$23.99M

Top Buyers

HolderShares% AssetsChange
Fmr6.34M0.02%1.39M
Avoro capital advisors4.15M3.43%1.38M
Paradigm biocapital advisors lp1.77M3.34%840.73K
Rtw investments, lp741.09K0.50%741.09K
Siren508.27K1.24%508.27K

Top Sellers

HolderShares% AssetsChange
Polar capital247.50K0.06%-852.50K
Camber capital management lp---441.00K
Finepoint capital lp---435.79K
Fred alger management295.62K0.06%-347.26K
Perceptive advisors---339.01K

New Positions

HolderShares% AssetsChangeValue
Rtw investments, lp741.09K0.50%741.09K$34.98M
Siren508.27K1.24%508.27K$23.99M
Silverarc capital management82.02K0.71%82.02K$3.87M
Dimensional fund advisors lp64.38K0.00%64.38K$3.49M
Jennison associates62.32K0.00%62.32K$2.94M

Sold Out

HolderChange
National bank of canada /fi/-2.00
Td private client wealth-9.00
Creative financial designs inc /adv-10.00
Amundi-12.00
Geneos wealth management-55.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2025145-2.03%58,588,368-0.85%921.06%63-11.27%5425.58%
Mar 31, 202515019.05%59,722,976-5.57%940.93%72-4343.33%
Dec 31, 20241246.90%63,224,5991.80%1001.03%70-3020.00%
Sep 30, 2024116-1.69%62,108,6632.42%981.05%7120.34%25-35.90%
Jun 30, 2024118-9.92%60,643,9062.22%961.08%59-6.35%39-7.14%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
T. Rowe Price Health Sciences1.04M1.64%-55.57K
Polar Capital Biotech S Inc1.00M1.58%-
Fidelity Growth Compy Commingled Pl S981.02K1.54%273.63K
Fidelity Growth Company Fund740.92K1.17%248.13K
Federated Hermes Kaufmann R665.00K1.05%-
Federated Hermes Kaufmann Growth665.00K1.05%-
US Small-Cap Growth II Equity Comp523.89K0.83%-134.19K
Fidelity Select Health Care520.00K0.82%-150.00K
Fidelity Select Biotechnology518.86K0.82%-86.20K
Federated Hermes Kaufmann Small Cap A503.00K0.79%-16.00K

Recent Insider Transactions

DateNameRoleActivityValue
Oct 08, 2025Bodenstedt Matthias Chief Financial OfficerBuy$98.81K
Sep 29, 2025Chen Bihua Former 10% OwnerSell$1.95M
Sep 29, 2025Chen Bihua Former 10% OwnerSell$25.70M
Sep 29, 2025Chen Bihua Former 10% OwnerSell$18.51M
Sep 29, 2025Chen Bihua Former 10% OwnerSell$663.62K

Insider Transactions Trends

DateBuySell
2025 Q41-
2025 Q3-6
2025 Q2--
2025 Q1--
2024 Q4-4

MLTX Ownership FAQ

Who Owns MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics shareholders are primarily institutional investors at 92.58%, followed by 15.33% insiders and -7.91% retail investors. The average institutional ownership in MoonLake Immunotherapeutics's industry, Biotech Stocks , is 307.10%, which MoonLake Immunotherapeutics falls below.

Who owns the most shares of MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics’s largest shareholders are Bvf inc/il (19.75M shares, 31.21%), Cormorant asset management, lp (8.49M shares, 13.42%), and Fmr (6.34M shares, 10.08%). Together, they hold 54.72% of MoonLake Immunotherapeutics’s total shares outstanding.

Does Blackrock own MoonLake Immunotherapeutics?

BlackRock is not among the top 10 institutional shareholders of MoonLake Immunotherapeutics.

Who is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested?

Bvf inc/il is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested, with 33.31% of its assets in 19.75M MoonLake Immunotherapeutics shares, valued at 932.26M$.

Who is the top mutual fund holder of MoonLake Immunotherapeutics shares?

T. Rowe Price Health Sciences is the top mutual fund holder of MoonLake Immunotherapeutics shares, with 1.64% of its total shares outstanding invested in 1.04M MoonLake Immunotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools